Product
RAVICTI
Aliases
Glycerol phenylbutyrate, GPB, HPN-100
Name
Ravicti
INN Name
glycerol phenylbutyrate
FDA Approved
Yes
3 clinical trials
1 organization
2 indications
1 document
Indication
Urea cycle disorderIndication
Corticobasal syndromeClinical trial
A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle DisordersStatus: Completed, Estimated PCD: 2022-07-05
Clinical trial
Double-blind, Randomised, Prospective, Placebo Controlled Parallel Group Phase II Study to Investigate the Effect of Glycerol Phenylbutyrate (GPB) on Neurofilament Light Chain (NfL) Levels in Patients With Corticobasal Syndrome (CBS)Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)Status: Completed, Estimated PCD: 2016-10-17
Document
DailyMed Label: RavictiOrganization
Horizon Therapeutics USA, Inc.